Sogroya for Turner Syndrome: FDA Approves First Weekly Growth Hormone for Girls With TS
FDA approves once-weekly Sogroya for growth failure in Turner syndrome. REAL8 data, side effects, limits and what it means for families.
FDA approves once-weekly Sogroya for growth failure in Turner syndrome. REAL8 data, side effects, limits and what it means for families.
Real-world data on 5,872 Ro patients show the once-daily Wegovy pill delivered 6.2% average weight loss in three months, slightly above trial results.
The EU has approved Novo Nordisk Frehemgo (denecimig), a monthly, fortnightly or weekly pen for haemophilia A with or without inhibitors.
FDA extended its denecimig review as manufacturing-site remediation continues. No efficacy or safety issues were cited; Novo now expects a US launch in H1 2027.